Mein Warenkorb

ADAM9

ADAM9 Molekülinformation

Englischer NameDisintegrin and metalloproteinase domain-containing protein 9Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2Target-AliasMeltrin-gamma,ADAM Metallopeptidase Domain 9 (Meltrin Gamma),Cellular disintegrin-related protein,ADAM 9,Metalloprotease/disintegrin/cysteine-rich protein 9,Mltng,MDC9,KIAA0021,Meltrin Gamma,CORD9,A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma),ADAM Metallopeptidase Domain 9,Cone Rod Dystrophy 9,MCMP,Myeloma cell metalloproteinase
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameDisintegrin and metalloproteinase domain-containing protein 9
Target-AliasMeltrin-gamma,ADAM Metallopeptidase Domain 9 (Meltrin Gamma),Cellular disintegrin-related protein,ADAM 9,Metalloprotease/disintegrin/cysteine-rich protein 9,Mltng,MDC9,KIAA0021,Meltrin Gamma,CORD9,A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma),ADAM Metallopeptidase Domain 9,Cone Rod Dystrophy 9,MCMP,Myeloma cell metalloproteinase
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

ADAM9 Molekülhintergrund

ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases.Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumoraggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers.Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.

ADAM9 Molekülalias

Disintegrin and metalloproteinase domain-containing protein 9 (EC:3.4.24.-) Cellular disintegrin-related protein,Meltrin-gamma,Metalloprotease,disintegrin,cysteine-rich protein 9,Myeloma cell metalloproteinase,ADAM9,KIAA0021, MCMP, MDC9, MLTNG

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Izeltabart tapatansineIMGC-936Phase 2 ClinicalImmunogen IncSolid tumours
Details
MGC-028MGC028; MGC-028Phase 1 ClinicalMacrogenics IncSolid tumours; Pancreatic Neoplasms; Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung
Details
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns